Início › Câncer de Mama › Arizona
Ensaios clínicos de Câncer de Mama em Arizona
57 estudos para Câncer de Mama estão buscando participantes em locais em Arizona.
Cidades em Arizona
- Phoenix25 estudos
- Tucson20 estudos
- Scottsdale18 estudos
- Gilbert9 estudos
- Goodyear6 estudos
- Chandler5 estudos
- Kingman4 estudos
Texto oficial do estudo (Inglês)
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Western Reg MC-COH Phoenix, Goodyear
RecrutandoFase 3
Idades de 18 a 100 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Kingman Regional Medical Center, Kingman
- Cancer Center at Saint Joseph's, Phoenix
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05334069A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Mayo Clinic Hospital, Phoenix
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06369285PRE-ISPY Phase I/II Oncology Platform Program
- Mayo Clinic Comprehensive Cancer Center, Phoenix
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT05868226Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
- Mayo Clinic, Scottsdale
RecrutandoFase 3
Idades 19 e acima · Mulheres · Atualizado em 29 de set. de 2026 · NCT05856773A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Gilbert
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT05877599Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- Mayo Clinic, Scottsdale
RecrutandoFase 2
Idades 50 e acima · Mulheres · Atualizado em 29 de set. de 2026 · NCT01766297A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- The University of Arizona Cancer Center - North Campus ( Site 0055), Tucson
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT07060807A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Banner MD Anderson Cancer Center ( Site 0066), Gilbert
- Mayo Clinic Cancer Center ( Site 0034), Phoenix
- University of Arizona Cancer Center ( Site 0035), Tucson
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06966700A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Ironwood Cancer & Research Centers ( Site 0066), Chandler
- Banner MD Anderson Cancer Center-Oncology ( Site 0004), Gilbert
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06312176The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Ironwood Cancer & Research Centers, Chandler
- Ironwood Cancer & Research Centers, Gilbert
- Ironwood Cancer & Research Centers, Glendale
- e mais 5
RecrutandoFase 3
Idades 60 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06377852Fucoidan for Preventing Chemotherapy-Related Fatigue in Patients With Gastrointestinal, Gynecological, Breast, or Lung Cancer
- Mayo Clinic in Arizona, Scottsdale
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06855524ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Mayo Clinic Building-Phoenix, Phoenix
- The University of Arizona Cancer Center - North Campus, Tucson
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07007559Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Mayo Clinic Arizona, Phoenix
- Honor Health Research Institute, Scottsdale
- University of Arizona Cancer Center, Tucson
Recrutando
Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT07214532A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Ironwood Cancer & Research Centers, Chandler
- Mayo Clinic in Arizona - Phoenix, Phoenix
- The University of Arizona Cancer Center - North Campus, Tucson
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07174336A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- Mayo Clinic in Arizona - Phoenix, Phoenix
RecrutandoFase 2
Idades 18 e acima · Mulheres · Atualizado em 22 de set. de 2026 · NCT07287098A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Banner Health MD Anderson AZ, Gilbert
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 21 de set. de 2026 · NCT05894239A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Ironwood Cancer and Research Centers, Chandler
- Banner MD Anderson Cancer Center, Gilbert
- Banner University Medical Center - Phoenix Campus (Banner Good Samaritan Medical Center), Phoenix
- e mais 3
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 15 de set. de 2026 · NCT06492616A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
- Mayo Clinic of Scottsdale, Scottsdale
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT05307705A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- University of Arizona Cancer Center, Tucson
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT07100106Breast Cancer, Reasoning, and Activity Intervention
- Mayo Clinic in Arizona, Phoenix
Recrutando
Idades 50 e acima · Mulheres · Atualizado em 8 de set. de 2026 · NCT04816006A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- HonorHealth, Scottsdale
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 4 de set. de 2026 · NCT06400472Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
- University of Arizona, Tucson
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 4 de set. de 2026 · NCT07287917Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Banner MD Anderson Cancer Center, Gilbert
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 3 de set. de 2026 · NCT06982521Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
- Mayo Clinic in Arizona, Scottsdale
RecrutandoFase 2
Idades 18 e acima · Mulheres · Atualizado em 3 de set. de 2026 · NCT06635980A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- City of Hope - Phoenix, Goodyear
- The Dignity Health Cancer Institute, Phoenix
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 3 de set. de 2026 · NCT06790693Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Kingman Regional Medical Center, Kingman
- Cancer Center at Saint Joseph's, Phoenix
- Mayo Clinic Hospital in Arizona, Phoenix
RecrutandoFase 3
Idades de 18 a 60 · Mulheres · Atualizado em 2 de set. de 2026 · NCT05879926Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Mayo Clinic-Comprehensive Cancer Center-Breast Clinic, Phoenix
- University of Arizona-Cancer Center, Tucson
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT06072612A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
- HonorHealth Research Institute, Scottsdale
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 26 de ago. de 2026 · NCT07383506Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
- Mayo Clinic Hospital in Arizona, Phoenix
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 17 de ago. de 2026 · NCT06500481Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer
- Mayo Clinic in Arizona, Scottsdale
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 12 de ago. de 2026 · NCT06525766Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- City of Hope - Cancer Center Phoenix, Goodyear
- Tucson Medical Center HealthCare, Tucson
RecrutandoFase 3
Idades de 18 a 100 · Todos os sexos · Atualizado em 6 de ago. de 2026 · NCT05232916Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR HonorHealth, Phoenix
- USOR Arizona Oncology Associates, Tucson
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 4 de ago. de 2026 · NCT05579366E-Mindfulness Approaches for Living After Breast Cancer
- Mayo Clinic Hospital in Arizona, Phoenix
RecrutandoFase 3
Idades de 18 a 50 · Todos os sexos · Atualizado em 4 de ago. de 2026 · NCT06748222Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
- University of Arizona Cancer Center - Prevention Research Clinic, Tucson
RecrutandoFase 2
Idades de 18 a 55 · Mulheres · Atualizado em 27 de jul. de 2026 · NCT06184750Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
- Investigative Site #108, Goodyear
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 23 de jul. de 2026 · NCT06545942A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Mayo Clinic Comprehensive Cancer Center, Phoenix
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 29 de jun. de 2026 · NCT05377996Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Mayo Clinic - Scottsdale, Scottsdale
- University of Arizona - Cancer Center, Tucson
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 22 de jun. de 2026 · NCT05696626A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Ironwood Cancer & Research Centers, Chandler
- Ironwood Cancer & Research Centers, Gilbert
- Ironwood Cancer & Research Centers, Glendale
- e mais 5
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 6 de mai. de 2026 · NCT07062965I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Mayo Clinic - Scottsdale, Scottsdale
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 6 de mai. de 2026 · NCT01042379Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.